William Blair analyst Bhavan Suri downgrades Qualtrics International (NASDAQ:XM) from Outperform to Market Perform.
Edgewise Receives Orphan Drug And Rare Pediatric Disease Designations For Its Muscular Dystrophy Program From FDA
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for
